ALLEN HEYD, PhD. Education: Purdue University. College of Pharmacy and
Pharmaceutical Sciences. Doctor of Philosophy, Pharmaceutics, 1968. Columbia
...
ALLEN HEYD, PhD
Education:
Purdue University College of Pharmacy and Pharmaceutical Sciences Doctor of Philosophy, Pharmaceutics, 1968 Columbia University College of Pharmaceutical Sciences Master of Science, Industrial Pharmacy, 1965 Bachelor of Science, Pharmacy, 1962
Professional Experience: 2000 – Present
ABSD Associates, LLC Medical Writing and Research Norwalk, Connecticut General Manager, consultant and medical writer • Serving the pharmaceutical industry and medical professionals in all phases of medical communications media. • Design, write and edit clinical study protocols and reports, monographs, IND and NDA submissions and manuscripts for publication. • Offer scientific research-related and technical services such as medical meeting and clinical trial monitoring. • Full service includes literature searches, literature reviews, data analysis, bibliographic referencing, fact-checking.
1980 – 2000
Bayer Corporation, Pharmaceutical Division West Haven, Connecticut Clinical Investigation, Anti-Infectives Section Deputy Director (1993 – 2000) • Served as technical and medical consultant to the Marketing group and company President on product issues and development planning. • Served on publication and clinical research committees to assist in writing clinical study publications, abstracts for national and international presentations. • Served on committee to review and approve clinical, pharmacokinetic or bacteriological research proposals from academic or medical institutions. • Directed investigators’ meeting start-up of clinical trials. • Served on committee responsible for hiring outside clinical trial managing companies for managing clinical trials. • Responsible for determining budgeting of clinical trials and supervising payment to trial investigators or other service companies. • Technical advisor to the marketing and marketing research groups at national or international meetings with specialty medical practitioners.
ALLEN HEYD, PhD
2 • •
Assisted in the search and interview process for hiring additional staffing in the department Responsible for training and overseeing Associate Directors in the department.
Associate Director (1985 – 1993) • Supervised Assistant Directors on clinical projects and served on scientific committees responsible for the development of new products. • Responsible for developing and writing clinical protocols, recruiting investigators, recruiting and supervising outside study managers (CROs). • Served on committee responsible for preparing publication manuscripts for publishing the results of clinical trials. • Responsible for the medical reports and summarization of data for NDA submissions. • Presented study results at national and international meeting. Assistant Director (1980 – 1985) • Assigned to team responsible for the development of Ciprofloxacin, the very first fluoroquinolone antibiotic. • Responsible for writing clinical study protocols, monitoring clinical trials in the field and writing medical reports on completion of clinical trials and data analysis. • Assisted in preparing NDA documents for submission to the FDA. 1970 – 1980
Vick Research Division of Richardson-Merrill, Inc. Mount Vernon, New York Section Head (1976 – 1980) • Head of oral hygiene product development laboratory. • Responsible for chairing monthly strategy meetings with all disciplines responsible in development of new products. • Coordinated consumer use tests and taste tests with market research on new products prior to market introduction. • Responsible for manufacture of all medications used in clinical efficacy and safety trials, taste testing studies and consumer use studies. • Responsible for writing complete product profile of new dosage forms developed for market introduction, together with Market Research manager. • Technical advisor to President of company and department heads on product design, integrity, quality and stability. Group Leader (1972 – 1976) • Head of oral hygiene product development laboratory. • Responsible for staff supervision, coordination with Marketing in the design and development of new dosage forms. • Responsible for supervising manufacturing line design for new products, and technical trouble shooting at the manufacturing plant.
ALLEN HEYD, PhD
3 Senior Scientist (1970 – 1972) • Responsible for basic research in dosage form design and development of oral hygiene products, including creams, ointments, gels, solutions and tablets.
1968 – 1970
Harilian Pharmaceuticals Greenwich, Connecticut Research Consultant •
• 1968 – 1970
Masti-Kure Products Co., Inc. Norwich, Connecticut Research Consultant • • •
1968 – 1970
Responsible for design and setup of equipment lines for manufacturing of veterinary solid, liquid, cream and ointment dosage forms. Responsible for design of all dosage form manufactured. Pharmaceutical scientific and technical advisor to President of the company.
University of Connecticut School of Pharmacy Assistant Professor of Pharmaceutics • •
Accomplishments:
Responsible for dosage form design of veterinary pharmaceuticals. Designed a tablet formulation that could be used for incorporating medications used in the treatment of animal diseases. Pharmaceutical scientific and technical advisor to President of the company.
Course responsibility for undergraduate and graduate industrial pharmacy and pharmacokinetics. Responsible for conducting industrial pharmacy research and research training of masters and doctoral candidates in pharmaceutics research.
Co-author and team member responsible for 10 NDA and 11 SNDA submissions (for various indications), including: Ciprofloxacin oral tablet, intravenous injection, oral suspension and otic suspension Moxifloxacin oral tablet and intravenous injection Vardenifil tablet Clotrimazole troche Bifonazole cream and solution • Author or co-author of 64 research publications • Member of the teams responsible for initial design, development, NDA submission and publication of the clinical trial data for the antibiotics’ Ciprofloxacin – Bayer’s largest selling world-wide antibiotic, and Moxifloxacin -- fastest drug development project in Bayer’s anti-infective history
•
ALLEN HEYD, PhD
4 • Member of the teams responsible for initial development, NDA submission and publication of the antifungals Clotrimazol Troche, Bifonazole Cream and Bifonazole Solution • Mentor to four newly hired Associate Directors in the Antiinfective Department at Bayer • Assisted the team that developed SOPs and templates for clinical study protocols and reports for Bayer • Consultant to the team writing the NDA submission for Vardenafil, an erectile dysfunction product at Bayer • Medical writer for nine medical reports for Faropenem Daloxate clinical trials.
Professional Affiliations: • • • •
American Society for Microbiology Associates of Clinical Pharmacology American Association of Pharmaceutical Scientists American Medical Writers Association
Honors and Distinctions: • Recipient of President’s Achievement and Quality Excellence Award (Premier Circle), 1998 • Special Recognition Award (Teamwork), 1999 • Bayer Corporation Award for 20 years of service, 2000 • Special Recognition Award (Above and beyond), 2000 • Recognition for Cipro® sNDA submission and approval for the treatment of anthrax, 2000 • Special recognition from Anti-infective Department for years of commitment, dedication and contribution to the department Civic Involvement and other: 1990 – present 1978 – 1982 1980 – 1985
Norwalk Seaport Association, Board of Trustees: Secretary, President (3 years), Treasurer (3 years) Norwalk Board of Education Secretary, Vice President, Chairman of Facilities Committee Norwalk High School Fathers’ Club President Fluent in German (written and spoken)
References upon request
ALLEN HEYD, PhD
5
SELECTED PUBLICATIONS
1. RAKKAR S; ROBERTS K; TOWE BF; FLORES SM; HEYD A; WARNER J. MOXIFLOXACIN VERSUS AMOXICILLIN CLAVULANATE IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS: A PRIMARY CARE EXPERIENCE. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ENGLAND) JUN 2001, 55 (5) P309-15. 2. HEYD A; HAVERSTOCK D. RETROSPECTIVE ANALYSIS OF THE SAFETY PROFILE OF ORAL AND INTRAVENOUS CIPROFLOXACIN IN A GERIATRIC POPULATION. CLINICAL THERAPEUTICS (UNITED STATES) OCT 2000, 22 (10) P1239-50. 3. DEABATE CA; MATHEW CP; WARNER JH; HEYD A; CHURCH D. THE SAFETY AND EFFICACY OF SHORT COURSE (5-DAY) MOXIFLOXACIN VS. AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS. RESPIRATORY MEDICINE (ENGLAND) NOV 2000, 94 (11) P1029-37. 4. PARISH LC; ROUTH HB; MISKIN B; FIDELHOLTZ J; WERSCHLER P; HEYD A; HAVERSTOCK D; CHURCH D. MOXIFLOXACIN VERSUS CEPHALEXIN IN THE TREATMENT OF UNCOMPLICATED SKIN INFECTIONS. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ENGLAND) OCT 2000, 54 (8) P497-503. 5. CHURCH D; PAINTER BG; HERRINGTON J; HAVERSTOCK D; WARNER JH; HEYD A. EFFICACY OF MOXIFLOXACIN IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS CAUSED BY PENICILLINRESISTANT STREPTOCOCCUS PNEUMONIAE 1. INT SYMP RESISTANT GRAM-POS INFECT, SAN ANTONIO, TX, USA, DEC 2000 6. KREIS SR; HERRERA N; GOLZAR N; FULLER HD; HEYD A. A COMPARISON OF MOXIFLOXACIN AND AZITHROMYCIN IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS J CLIN OUTCOMES MANAGEMENT 7 (12): 33-37 (2000) 7. ABATE CA DE; MATHEW CP; WARNER JH; HEYD A; CHURCH D. THE SAFETY AND EFFICACY OF SHORT COURSE (5-DAY) MOXIFLOXACIN VS.AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS. RESPIR MED 94 (11): 1029-1037 (2000) 8. CHURCH D; HAVERSTOCK D; HEYD A. MOXIFLOXACIN: A REVIEW OF ITS SAFETY PROFILE BASED ON WORLDWIDE CLINICAL TRIALS. INT PHARM ABSTR 57 (6): 792 ABSTR 3705310//P23 (2000) 9. BAZ MN; JANNETTI W; VILLANUEVA C; BURKE T; PAUSE C; WANG L; CHURCH D; HEYD A. THE EFFICACY AND TOLERABILITY OF MOXIFLOXACIN COMPARED TO TROVAFLOXACIN IN THE TREATMENT OF ACUTE SINUSITIS. TODAYS THER TRENDS 17 (4): 303-319 (1999) 10. BURKE T; VILLANUEVA C; MARIANO H; HUCK W; ORCHARD D; HAVERSTOCK D; HEYD A; CHURCH D. COMPARISON OF MOXIFLOXACIN AND CEFUROXIME AXETIL IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS. CLIN THER 21 (10): 1664-1677 (1999)
ALLEN HEYD, PhD
6
11. PISTORIUS B; WESTBERRY K; DREHOBL M; WILLIAMS D; BOCK T; LUCENTE FE; SHAN M; PERRONCEL R; HEYD A. PROSPECTIVE, RANDOMIZED, COMPARATIVE TRIAL OF CIPROFLOXACIN OTIC DROPS, WITH OR WITHOUT HYDROCORTISONE, VS.POLYMYXIN BNEOMYCIN-HYDROCORTISONE OTIC SUSPENSION IN THE TREATMENT OF ACUTE DIFFUSE OTITIS EXTERNA. INFECT DIS CLIN PRACT 8 (8): 387-395 (1999) 12. GOMOLIN IH; SIAMI P; HAVERSTOCK D; HEYD A. EFFICACY AND SAFETY OF CIPROFLOXACIN ORAL SUSPENSION VS TMP/SMX FOR TREATMENT OF COMMUNITY- AND NURSING HOMERESIDING ELDERLY WOMEN WITH ACUTE URINARY TRACT INFECTION. J AM GERIATR SOC 47 (9): S 39 ABSTR P111 (1999) 13. BAZ M; PAUSE C; WANG L; CHURCH D; HEYD A. MOXIFLOXACIN VERSUS TROVAFLOXACIN IN THE TREATMENT OF ACUTE SINUSITIS. THIRTY NINTH INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, ICAAC, SAN FRANCISCO, USA, SEP 1999: 709 ABSTR 171 (1999) 14. BURKE T; VILLANUEVA C; MARIANO H; HUCK W; ORCHARD D; HAVERSTOCK D; HEYD A; CHURCH D. MOXIFLOXACIN VERSUS CEFUROXIME AXETIL IN THE TREATMENT OF ACUTE SINUSITIS39. INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, ICAAC, SAN FRANCISCO, USA, SEP 1999: 709 ABSTR 170 (1999) 15. PARISH LC; HEYD A; HAVERSTOCK D; CHURCH D. EFFICACY AND SAFETY OF MOXIFLOXACIN VERSUS CEPHALEXIN IN THE TREATMENT OF MILD TO MODERATE UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS. J ANTIMICROB CHEMOTHER 44 (SUPPL A): 137-138 ABSTR P441 (1999) 21. INT CONGR CHEMOTHER, ICC, BIRMINGHAM, UK, JUL 1999 16. CLIFFORD K; HUCK W; SHAN M; TOSIELLO R; ECHOLS RM; HEYD A. DOUBLE-BLIND COMPARATIVE TRIAL OF CIPROFLOXACIN VERSUS CLARITHROMYCIN IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS ANN OTOL RHINOL LARYNGOL 108 (4 PT 1): 360-367 (1999) 17. MCCARTY JM; RICHARD G; HUCK W; TUCKER RM; TOSIELLO RL; SHAN M; HEYD A; ECHOLS RM. A RANDOMIZED TRIAL OF SHORT-COURSE CIPROFLOXACIN, OFLOXACIN, OR TRIMETHOPRIM/SULFAMETHOXAZOLE FOR THE TREATMENT OF ACUTE URINARY TRACT INFECTION IN WOMEN. AM J MED 106 (3): 292-299 (1999) 18. JOHNSON PA; RODRIGUEZ HP; WAZEN JJ; HUCK W; SHAN M; TOSIELLO R; HEYD A; ECHOLS RM. CIPROFLOXACIN VERSUS CEFUROXIME AXETIL IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS. J OTOLARYNGOL 28 (1): 3-12 (1999) 19. HEYD A; SHAH A; LIU MC; VAUGHAN D; HELLER AH. ORAL BIOEQUIVALENCE AND EFFICACY OF CIPROFLOXACIN (CIP) SUSPENSION (SUSP) FOR TREATMENT OF ACUTE URINARY TRACT INFECTION (UTI). 38. INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, ICAAC, SAN DIEGO, CALIFORNIA, USA, SEP 1998: 572 ABSTR L-82 (1998) 20. LILDHOLDT T; HAMPEL B; SHAN M; HEYD A. CIPROFLOXACIN VS.CIPROFLOXACIN/HYDROCORTISONE, VS.POLYMYXIN B-NEOMYCIN-HYDROCORTISONE OTIC DROPS FOR TREATMENT OF ACUTE DIFFUSE OTITIS EXTERNA. 8. INT CONGR INFECT DIS, ICID, BOSTON, USA, MAY 1998: 204 ABSTR 59.036 (1998) 21. HUCK W; SHAN M; TOSIELLO R; HEYD A. DOUBLE-BLIND COMPARATIVE TRIAL OF CIPROFLOXACIN VS CLARITHROMYCIN IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS. ANN ALLERGY ASTHMA IMMUNOL 80: 114 ABSTR P57 (1998)
ALLEN HEYD, PhD
7
22. KLEIN GL; WHALEN E; ECHOLS RM; HEYD A. CIPROFLOXACIN VERSUS CEFUROXIME AXETIL IN THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SINUSITIS. J OTOLARYNGOL 27 (1): 10-16 (1998) 23. JOHNSON P; HEYD A; ARVIS P. EFFICACY OF ORAL CIPROFLOXACIN IN TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATIONS OF CHRONIC SINUSITIS. PHARMACOTHERAPY 17: 1098 ABSTR 114 (1997) 24. ECHOLS R; HEYD A; TOSIELLO R; BLOCK A. CIPROFLOXACIN IN THE TREATMENT OF CHRONIC BACTERIAL PROSTATITIS. CAN J INFECT DIS 6 (SUPPL C): 415C ABSTR 3147 (1995) 19. INT CONGR CHEMOTHER (ICC), MONTREAL, CANADA, JULY 95 25. IRAVANI A; HEYD A; TOSIELLO R; BLOCK A; ECHOLS R.LOW-DOSE, SHORT-COURSE CIPROFLOXACIN TREATMENT OF ACUTE URINARY TRACT INFECTION (UTI) IN WOMEN CAN J INFECT DIS 6 (SUPPL C): 415C ABSTR 3148 (1995) 19. INT CONGR CHEMOTHER (ICC), MONTREAL, CANADA, JULY 95 26. HEYD A; ECHOLS R; SHAN M; TOSIELLO R; WILSON K. ORAL CIPROFLOXACIN VS CEFUROXIME IN THE TREATMENT OF ACUTE SINUSITIS. 35. INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER (ICAAC), SAN FRANCISCO, CALIFORNIA/USA, SEPTEMBER: 332 ABSTR LM31 (1995) 27. ECHOLS RM; HEYD A; TOSIELLO LR; BUSCH W; SCHACHT P. EFFICACY AND SAFETY OF CIPROFLOXACIN FOR CHRONIC BACTERIAL PROSTATITIS INFECT MED 12 (6): 283-290 (1995) 28. IRAVANI A; TICE AD; MCCARTY J; SIKES DH; NOLEN T; GALLIS HA; WHALEN EP; TOSIELLO RL; HEYD A; KOWALSKY SF; ECHOLS RM. SHORT-COURSE CIPROFLOX TREATMENT OF ACUTE UNCOMPLICATED URINARY TRACT INFECTION IN WOMEN: THE MINIMUM EFFECTIVE DOSE ARCH INTERN MED 155: 485-494 (1995) 29. TRAUB S; TICE A; HEYD A. PROSPECTIVE RANDOMIZED, DOUBLE-BLIND COMPARISON OF 3DAY THERAPY WITH CIPROFLOXACIN 100 MG BID TRIMETHOPRIM/SULFAMETHOXAZOLE 160/800 MG BID, AND OFLOXACIN 200 MG BID FOR ACUTE UNCOMPLICATED LOWER URINARY TRACT INFECTION. PHARMACOTHERAPY 15 (1): 112 ABSTR 35E (1995) 30. MCCARTY JAMES M; RICHARD GEORGE; HUCK WERNER; TUCKER RICHARD M; TOSIELLO ROBERT L; SHAN MICHAEL; HEYD A; ECHOLS ROGER M; CIPROFLOXACIN URINARY TRACT INFECTION GROUP. A RANDOMIZED TRIAL OF SHORT-COURSE CIPROFLOXACIN, OFLOXACIN, ORTRIMETHOPRIM/SULFAMETHOXAZOLE FOR THE TREATMENT OF ACUTE URINARY TRACT INFECTION IN WOMEN. AMERICAN JOURNAL OF MEDICINE 106 (3): P 292-299 MARCH, 1999
31. ECHOLS RM; HEYD A; O’KEEFFE BJ; SCHACHT P. SINGLE-DOSE CIPROFLOXACIN FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA.A WORLDWIDE SUMMARY. SEX TRANSM DIS 21 (6): 345-352 (1994) 32. KLEIN GL; HEYD A; ECHOLS R. ORAL CIPROFLOXACIN VS CEFUROXIME AXETIL IN ACUTE BACTERIAL SINUSITIS: A PILOT STUDY IN ADULTS. DRUGS 45 (SUPPL 3): 324 (1993)
ALLEN HEYD, PhD
8
33. TRAUB SL; TICE A; HEYD A; ECHOLS R. PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, COMPARISON OF 100 MG BID THREE-DAY, AND 250 MG BID SEVEN-DAY CIPROFLOXACIN THERAPY IN FEMALE PATIENTS WITH UNCOMPLICATED LOWER URINARY TRACT INFECTIONS PHARMACOTHERAPY 13 (3): 279-280 ABSTR 78E (1993) 34. IRAVANI A; HEYD A; ECHOLS R. PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE DIFFERENT DOSAGES OF ORAL CIPROFLOXACIN (CIP) IN FEMALES WITH UNCOMPLICATED LOWER URINARY TRACT INFECTION. 4. INT SYMP NEW QUINOLONES, MUNICH WG, P 201 ABSTR 164 (1992) 35. WILSON W; HEYD A; ECHOLS R. PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF SINGLE- DOSE (SD) VS MULTI-DOSE (MD) CIPROFLOXACIN (CIP) IN FEMALE PATIENTS WITH UNCOMPLICATED LOWER URINARY TRACT INFECTION (CYSTITIS) 4. INT SYMP NEW QUINOLONES, MUNICH WG, P 205 ABSTR 168 (1992) 36. HEYD A; ECHOLS RM; O’KEEFFE BJ; SCHACHT P. ORAL CIPROFLOXACIN (CIP) SINGLE DOSE TREATMENT OF UNCOMPLICATED UROGENITAL AND EXTRAGENITAL GONOCOCCAL INFECTIONS - A WORLD WIDE SUMMARY 4. INT SYMP NEW QUINOLONES, MUNICH WG, P 232 ABSTR 190 (1992) 37. BARASH M; KHAN F; CLARK R; HEYD A; SELIGMAN M. EFFICACY AND SAFETY OF ORAL CIPROFLOXACIN VERSUS AMOXICILLIN / CLAVULANATE IN THE TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS IN ADULTS. EUR RESPIR J SUPPL 5 (15): 331 ABSTR 1104 (1992) 38. HEYD A; SELIGMAN M. USE OF CIPROFLOXACIN FOR THE TREATMENT OF INFECTIONS DUE TO STAPHYLOCOCCI. 17 INTERNAT CONGRESS OF CHEMOTHERAPY, ICC 91, BERLIN, JUNE 1991, EDS: PAUL EHRLICH GESELLSCHAFT FUER CHEMOTHERAPIE, FUTURAMED, MUENCHEN, 1991: ABSTR 1003: (1991) 39. BARASH M; KHAN F; CLARK R; HEYD A; SELIGMAN M. EFFICACY AND SAFETY OF ORAL CIPROFLOXACIN VERSUS AMOXYCILLIN-CLAVULANATE IN THE TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS IN ADULTS. EUR J CLIN MICROBIOL INFECT DIS 10 (SUPPL): 8-10 (1991) 40. SAKHRANI LM; MENDEZ R; MEZA C; HEYD A; ROGGE M. PHARMACOKINETIC INTERACTION BETWEEN CYCLOSPORIN A AND CIPROFLOXACIN (CIPRO). 3. INT SYMP NEW QUINOLONES VANCOUVER JULY 1990: 534 ABSTR 430 41. ARCIERI G; GRIFFITH E; GRUENWALD G; HEYD A; OBRIEN B. CIPROFLOXACIN: A REVIEW OF CLINICAL EXPERIENCE ARQ BRAS MED 63 (4): 327-332 (1989) 42. FROST RW; CARLSON JD; DIETZ AJ; HEYD A; LETTIERI JT. CIPROFLOXACIN PHARMACOKINETICS AFTER A STANDARD OR HIGH-FAT / HIGH-CALCIUM BREAKFAST. J CLIN PHARMACOL 29 (10): 953-955 (1989) 44. ARCIERI GM; BECKER N; ESPOSITO B; GRIFFITH E; HEYD A; NEUMANN C; OBRIEN B; SCHACHT P. SAFETY OF INTRAVENOUS CIPROFLOXACIN.A REVIEW. AM J MED 87 (SUPPL 5 A): 92-97 (1989)
ALLEN HEYD, PhD
9
45. ARCIERI G; GRIFFITH E; GRUENWALDT G; HEYD A; OBRIEN B. A SURVEY OF CLINICAL EXPERIENCE WITH CIPROFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL. J CLIN PHARMACOL 28 (2): 179-189 (1988) 46. GOODWIN SD; NIX DE; HEYD A; ARENA JV; SCHENTAG JJ. COMPATIBILITY OF CIPROFLOXACIN IN INTRAVENOUS ADMIXTURES. ASHP MIDYEAR CLIN MEET 23: 162 ABSTR P217 E (1988) 47. CARLSON JH; DIETZ AJ; HERTSGAARD DM; HEYD A; FROST RW; LETTIERI JT. CIPROFLOXACIN BIOAVAILABILITY AFTER A STANDARD OR HIGH-CALCIUM MEAL. PHARM RES 5 (10 SUPPL): S166 ABSTR PP 1269 (1988) 48. GONZALEZ M; MAGANA J; HEYD A; LETTIERI J; KROL G; LITTLE M. THE EFFECT OF FOOD ON THE BIOAVAILABILITY OF CIPROFLOXACIN. PHARM RES 4 (2 SUPPL): S94 ABSTR PP-661 (1987) 49. ARCIERI G; GRIFFITH E; GRUENWALDT G; HEYD A; O'BRIEN B. CIPROFLOXACIN: AN UPDATE ON CLINICAL EXPERIENCE. AM J MED 82 (SUPPL 4A): 381-386 (1987) 50. LETTIERI J; GONZALEZ M; HEYD A; KROL G; MAGANA J; ARCIERI G. PHARMACOKINETICS OF ORAL CIPROFLOXACIN AND METABOLITES IN RENAL IMPAIRMENT. CLIN PHARMACOL THER 41 (2): 167 ABSTR PPC 5 (1987) 51. ARCIERI G; AUGUST R; BECKER N; DOYLE C; GRIFFITH E; GRUENWALDT G; HEYD A; OBRIEN B. CLINICAL EXPERIENCE WITH CIPROFLOXACIN IN THE USA. EUR J CLIN MICROBIOL 5 (2): 220-225 (1986) 52. HEYD A; DHABHAR DJ. PARTICLE SHAPE EFFECT ON CAKING OF COURSE CONCENTRATED ANTACID SUSPENSIONS. DRUG COSMETIC INDUSTRY, 125: 42 (1979) 53. LINDSTROM RE; PAWELCHAK J; HEYD A; TARBET WJ. PHYSICAL-CHEMICAL ASPECTS OF DENTURE RETENTION AND STABILITY: A REVIEW OF THE LITERATURE. JOURNAL OF PROSTHETIC DENTISTRY, OCT 1979, 42 (4) 371-5 54. HEYD A; DHABHAR DJ. MOUTHWASH COMPOSITIONS. US PATENT 4,130,638 (1978) 55. MO Y; PECK GE; HEYD A; BANKER GS. RECORDING PH METHOD OF CHARACTERIZING COMPOSITION AND MONITORING DISSOLUTION PROFILE OF AN ANHYDRIDE-ACID COPOLYMER AND ITS SALT DERIVATIVES. JOURNAL OF PHARMACEUTICAL SCIENCES, MAY 1977, 66 (5) 713-7 56. HEYD A; DHABHAR DJ. ENHANCING FLUIDITY OF CONCENTRATED ANTACID SUSPENSIONS. JOURNAL OF PHARMACEUTICAL SCIENCES, OCT 1975, 64 (10) 1697-9
57. HEYD A. THE ROLE OF AUTOMATION IN SUGAR COATING TABLETS. DRUG DEVELOPMENT COMMUNICATIONS, 1 (2), 133-142 (1974-75) 58. HEYD A. VARIABLES INVOLVED IN AN AUTOMATED TABLET-COATING SYSTEM. JOURNAL OF PHARMACEUTICAL SCIENCES, MAY 1973, 62 (5) 818-20 59. HEYD A. POLYMER-DRUG INTERACTION: STABILITY OF AQUEOUS GELS CONTAINING NEOMYCIN SULFATE. JOURNAL OF PHARMACEUTICAL SCIENCES, SEP 1971, 60 (9) 1343-45
ALLEN HEYD, PhD
10
60. HEYD A. MACROMOLECULAR DISSOLUTION. TEMPERATURE EFFECTS ON POLYMER-DRUG PREPARATION. JOURNAL OF PHARMACEUTICAL SCIENCES, OCT 1970, 59 (10) 1526-7 61. HEYD A; KANIG JL. IMPROVED SELF-PROGRAMMING AUTOMATED TABLET-COATING SYSTEM. JOURNAL OF PHARMACEUTICAL SCIENCES, AUG 1970, 59 (8) 1171-4 62. HEYD A; KILDSIG DO; BANKER GS. DISSOLUTION OF MACROMOLECULES. II. DISSOLUTION OF AN ETHYLENE--MALEIC ACID COPOLYMER.. JOURNAL OF PHARMACEUTICAL SCIENCES, JULY 1970, 59 (7) 947-9 63. HEYD A; KILDSIG DO; BANKER GS. DISSOLUTION OF MACROMOLECULES. I. SURFACE PHENOMENA ASSOCIATED WITH POLYMER DISSOLUTION. JOURNAL OF PHARMACEUTICAL SCIENCES, MAY 1969, 58 (5) 586-8 64. HEYD A. QUALITY ASSURANCE IN DRUG MANUFACTURING-PACKAGING. PROCEEDINGS EASTERN REGIONAL PMA-FDA SIMINAR, RUTGERS UNIVERSITY EXTENSION SERVICE, NEW BRUNSWICK, NEW JERSEY. (1969), 55
